“When Heptares formed, we chose to focus on GPCRs because we knew that targeting these receptors leads to drugs,” says Matt Barnes, president and head of R&D at Nxera Pharma. GPCRs are ...

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor appetite for its G protein-coupled receptors (GPCRs). The South San ...

Structure Therapeutics Inc. (NASDAQ:GPCR) was able to report positive results from its phase 2a study using its GLP-1R agonist GSBR-1290 for the treatment of patients with obesity in June 2024.

G protein–coupled receptors (GPCRs) are one of the most popular target classes investigated in the drug-discovery process. With its selection of kits (cAMP femto, cAMP dynamic and cAMP HiRange ...

The company noted that the collaboration combines Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-specific libraries,’ with Nxera’s ...

Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza Rinascimento 6, Urbino 61029, Italy ...